Revolutionary therapy! GLP-1 medication drastically reduce risk in psoriasis

Revolutionary therapy! GLP-1 medication drastically reduce risk in psoriasis

At this year's Congress of the European Academy of Dermatology and Venereology (EADV), a groundbreaking study was presented that shows a dramatic reduction in the death and cardiovascular risk in psoriasis patients treated with GLP-1 receptor agonists (GLP-1RAS). These drugs have reduced the death rate by 78 % and reduced the risk of serious cardiovascular events by 44 % compared to patients who take other diabetes or weight reduction medication. The study is the largest of its kind and analyzed data from over 110 million patients in the United States.

Research focused on over 6,000 psoriasis patients with diabetes or obesity over a period of two years. 3,048 patients received GLP-1RAS, while the rest received the standard therapy. Professor Ralf Ludwig, the main author of the study, explained that the advantages of GLP-1RAS remained consistent in all sensitivity analyzes, regardless of age, gender and side diseases.

Advantages and side effects

A remarkable aspect of the study is that GLP-1RAS can reduce the risk of alcohol abuse by 65 % and the risk of drug abuse by almost 50 %. These resulting advantages are particularly important because psoriasis patients often also experience mental illnesses. Psychiatric problems are common in psoriasis, which affects 2-3 % of the population, and the disease is also associated with an increased risk of heart attacks, strokes and other cardiometabolic comorbidities, as has been determined in previous studies.

GLP-1RAS, which include medication such as Semaglutid and Liraglutid, are primarily approved for the treatment of type 2 diabetes and obesity, but also show promising results in the improvement of psoriasis. While some studies delivered contradictory results, most indicate that these medication can offer both cardiocoders' advantages and improvements in psoriatic symptoms.

A promising approach

The researchers' hypothesis suggests that the activation of GLP-1 receptors could inhibit pro-inflammatory mediators that are increased in psoriasis (an immune-mediated skin disease). GLP-1 receptors can also be found in brain regions associated with mood and reward systems. The safety of the treatment was also examined in the studies. The results showed that the side effects were not significantly increased compared to the general population, which makes GLP-1RAS a preferred treatment option for psoriasis patients with accompanying diabetes or weight anomalies.

In summary, research on GLP-1RAS is promising and suggests that they not only improve the psoriatic symptoms, but can also significantly reduce the risk of cardiovascular diseases. The need for further examinations remains to understand the exact mechanisms and long -term effects of this promising therapy. Doctors are advised to carry out annual screenings for psoriasis patients in order to recognize the development of psoriasis arthritis and cardiovascular diseases at an early stage. The current results underline the importance of monitoring this patient population and the consideration of GLP-1RAS as a possible therapy option [ots] and [PubMed] as well as [PMC].